Al Amyloidosis
📧 Sign up to get email alerts when something new happens for Al Amyloidosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-02-17Clinical Trial Update: Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis [Phase 1, Phase 2]
A Phase 1/2a clinical trial is investigating belantamab mafodotin for relapsed or refractory AL amyloidosis; the study is currently recruiti…
-
CLINICAL_TRIALS trial_result · 2026-01-26Clinical Trial Update: Safety and Efficacy of GPRC5D CAR-T Cell Therapy in Relapsed/Refractory Plasma Cell Disorders [EARLY_Phase 1]
An early-phase Phase 1 trial evaluating a GPRC5D-targeted CAR-T cell therapy for relapsed/refractory plasma cell disorders, with the study n…
-
CLINICAL_TRIALS trial_result · 2026-01-13Clinical Trial Update: Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis [Phase 2]
Phase 2 clinical trial evaluating sonrotoclax plus dexamethasone with or without daratumumab in patients with t(11;14) positive primary AL a…
-
CLINICAL_TRIALS research · 2025-12-31Clinical Trial Update: Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE) [Phase 2]
Phase 2 clinical trial evaluating minimal residual disease–driven deferral of transplant in dysproteinemia, including multiple myeloma and A…
-
CLINICAL_TRIALS trial_result · 2025-12-04Clinical Trial Update: Ixazomib Maintenance Study in Patients With AL Amyloidosis [Phase 2]
A Phase 2 study evaluating ixazomib as maintenance therapy for AL amyloidosis, with the trial currently active and not recruiting.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-11-25Clinical Trial Update: Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis [Phase 3]
This Clinical Trial Update describes a Phase 3 study evaluating the efficacy of the PET tracer Florbetaben (18F) for diagnosing cardiac AL a…
-
CLINICAL_TRIALS research · 2025-11-04Clinical Trial Update: Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis [Phase 2]
A Phase 2 clinical trial evaluating whether siltuximab can reduce symptom burden after autologous stem cell transplantation in patients with…
-
CLINICAL_TRIALS research · 2025-10-10Clinical Trial Update: Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant. [Phase 1]
Phase 1 study evaluating Captisol-enabled melphalan pharmacokinetics in patients with multiple myeloma or AL amyloidosis undergoing autologo…
-
CLINICAL_TRIALS research · 2025-09-15Clinical Trial Update: Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis [Phase 3]
Phase 3 trial update comparing Dara-VCD chemotherapy with autologous stem cell transplant versus Dara-VCD chemotherapy alone in newly diagno…
-
CLINICAL_TRIALS trial_result · 2025-09-05Clinical Trial Update: A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis [Phase 2]
Phase 2 study evaluating belantamab mafodotin in relapsed or refractory AL amyloidosis has completed. The trial was conducted under the Stic…
-
CLINICAL_TRIALS research · 2025-08-06Clinical Trial Update: Screening for AL Amyloidosis in Smoldering Multiple Myeloma
This clinical trial update indicates ongoing recruitment for a study screening for AL amyloidosis in people with smoldering multiple myeloma…
-
CLINICAL_TRIALS research · 2025-08-05Clinical Trial Update: Multimodal Radiomics Model (18F-FAPI PET/CT + CMR) for AL Cardiac Amyloidosis Prognosis
A clinical trial update describes a multimodal radiomics model using 18F-FAPI PET/CT plus cardiac MRI to predict prognosis in AL amyloidosis…
-
CLINICAL_TRIALS research · 2025-07-25Clinical Trial Update: Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research [EARLY_Phase 1]
This document reports an EARLY Phase 1 clinical trial evaluating Meta10-BCMA for relapsed/refractory plasma cell neoplasms. The therapy uses…
-
CLINICAL_TRIALS research · 2025-07-23Clinical Trial Update: Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis [Phase 2]
Phase 2 clinical trial evaluating teclistamab in newly diagnosed Mayo Stage IIIB AL amyloidosis is currently recruiting.
-
CLINICAL_TRIALS research · 2025-07-10Clinical Trial Update: Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis [Phase 1, Phase 2]
Nexcella Inc. is conducting a Phase 1/2 clinical trial of the CAR-T therapy NXC-201 to treat AL amyloidosis, currently recruiting.
-
CLINICAL_TRIALS research · 2025-07-09Clinical Trial Update: Study of Eque-cel CAR-T Therapy in Newly Diagnosed Severe AL Amyloidosis [Phase 2]
This clinical trial update notes a Phase 2 study of Eque-cel CAR-T therapy for newly diagnosed severe AL amyloidosis, which is currently not…
-
CLINICAL_TRIALS research · 2025-07-08Clinical Trial Update: Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis [Phase 1, Phase 2]
A Phase 1/2 trial evaluating the combination of venetoclax and dexamethasone for relapsed or refractory AL amyloidosis with t(11;14) translo…
-
CLINICAL_TRIALS trial_result · 2025-05-01Clinical Trial Update: Nutritional Counseling in Systemic Immunoglobulin Light-chain Amyloidosis [NA]
A completed clinical trial evaluating nutritional counseling in patients with systemic AL amyloidosis.
-
CLINICAL_TRIALS trial_result · 2025-03-05Clinical Trial Update: A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis [Phase 2]
A Phase 2 study evaluating CAEL-101 (birtamimab) for safety and tolerability in patients with AL amyloidosis has completed. Results were pos…
-
CLINICAL_TRIALS research · 2025-03-03Clinical Trial Update: The Norwegian Immunotherapy in Multiple Myeloma Study
The Norwegian immunotherapy in multiple myeloma study (NCT06855121) is currently recruiting. It targets multiple myeloma, plasma cell leukem…
-
CLINICAL_TRIALS trial_result · 2025-02-20Clinical Trial Update: Daratumumab and Pomalidomide in Previously Treated Patients With AL Amyloidosis [Phase 2]
The Phase 2 trial evaluating daratumumab plus pomalidomide in previously treated AL amyloidosis was terminated.
-
CLINICAL_TRIALS trial_result · 2025-02-07Clinical Trial Update: Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis [Phase 1]
This entry reports the completion of a Phase 1 clinical trial evaluating a chimeric fibril-reactive monoclonal antibody designated 11-1F4 in…
-
CLINICAL_TRIALS research · 2025-01-10Clinical Trial Update: BCMA/CD3 BiTE for RRAL or NDAL Amyloidosis With Insufficient Depth of Hematologic Response After Induction Therapy [NA]
Clinical trial update for a BCMA/CD3 bispecific T-cell engager in AL amyloidosis (relapsed/refractory or newly diagnosed) noting insufficien…
-
CLINICAL_TRIALS trial_result · 2024-11-12Clinical Trial Update: Molecular Imaging of the Underlying Mechanism of Cardiotoxicity in Patients With Light Chain Amyloidosis Using PET/CT [EARLY_Phase 1]
An early-phase trial evaluating molecular imaging with PET/CT to understand the mechanism of cardiotoxicity in patients with light-chain (AL…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis [Phase 1, Phase 2]
A Phase 1/2 study of ZN-d5 for relapsed or refractory AL amyloidosis has completed.